Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Rhea-AI Summary
Seer (Nasdaq: SEER)/b) announced that a Special Committee of its Board, composed of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected an unsolicited, non-binding proposal dated July 1, 2026 from Chair and CEO Omid Farokhzad, M.D. to acquire all outstanding shares of Seer’s Class A common stock for
The Special Committee, advised by independent advisors, determined the proposal is not in the best interests of stockholders because it undervalues Seer and does not reflect its long-term growth prospects. It also concluded that the CVRs, intended to allow stockholders to benefit from future developments related to Seer’s technology, are insufficient to fully value Seer and its growth potential.
Positive
- Unanimous rejection of $2.45 per-share offer plus CVRs as undervaluing Seer
- Independent Special Committee formed with external advisors to evaluate CEO-led proposal
- Board emphasizes long-term growth prospects as key factor in dismissing the transaction terms
Negative
- None.
News Market Reaction – SEER
In the Jul 20 session, SEER declined 5.99%, reflecting a notable negative market reaction. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 06 | Acquisition response | Positive | +35.2% | Radoff-JEC Group responded to the CEO’s acquisition proposal |
| Jul 02 | Acquisition proposal | Positive | +35.2% | Seer disclosed receipt of the CEO’s unsolicited acquisition proposal |
| May 27 | Acquisition appeal | Positive | +2.1% | Radoff-JEC Group urged reconsideration of its premium acquisition proposal |
| May 14 | Acquisition proposal | Positive | -1.1% | Radoff-JEC Group submitted its third non-binding acquisition proposal |
| Apr 29 | Acquisition response | Negative | -2.6% | Radoff-JEC Group responded to Seer’s rejection of an acquisition proposal |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five tag-specific acquisition events ranged from -2.59% to +35.19%, averaging a 13.76% 24-hour move.
Key Terms
proteomic technical
contingent value rights financial
fiduciary duties regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for
Consistent with its fiduciary duties, the Special Committee carefully reviewed the Proposal in consultation with its independent advisors and unanimously determined that it is not in the best interests of Seer’s stockholders because it undervalues Seer and fails to reflect the value of Seer’s long-term growth prospects. In reaching this conclusion, the Special Committee noted that the contingent value rights included in the Proposal, which are intended to allow Seer’s stockholders to benefit from future developments related to Seer’s technology, were insufficient to fully value Seer and its growth potential.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at pr@seer.bio.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s prospects, growth potential and technology. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
investor@seer.bio
